Policy / Regulatory

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
NHC (NHFPC)NMPA

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China's Ministry of Public Security (MPS), the National Health Commission (NHC), and the National Medical Products Administration (NMPA) jointly issued an announcement deciding to list the entire class of "orphine‑type…

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CDEGQCE testing

CDE Seeks Public Input on Latest Batch of Generic Chemical Reference Preparations

China’s NMPA Proposes Expedited Review for Clinically Urgent Overseas Drugs

COVID-19

U.S. Lawmakers Question FDA on Discrepancies in Foreign Inspections of China and India

State Council

Hefei Airport Port Designated as Drug Import Port by Chinese Authorities

Show More